E775874C-4CE0-4D23-8CF0-7A3D72A84DD9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.816031537450723
- age_years
- 52
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- NOTCH_SIGNALING+0.406
- DNA_REPAIR+0.403
- ADIPOGENESIS+0.370
- OXIDATIVE_PHOSPHORYLATION+0.351
- MYC_TARGETS_V2+0.340
- CHOLESTEROL_HOMEOSTASIS+0.329
- INTERFERON_GAMMA_RESPONSE+0.323
- P53_PATHWAY+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.319
Top 10 suppressed
- KRAS_SIGNALING_DN-0.224
- UV_RESPONSE_DN-0.207
- SPERMATOGENESIS-0.165
- APICAL_JUNCTION-0.157
- MITOTIC_SPINDLE-0.142
- APICAL_SURFACE-0.103
- G2M_CHECKPOINT-0.089
- ESTROGEN_RESPONSE_EARLY-0.080
- HEDGEHOG_SIGNALING-0.076
- ANGIOGENESIS-0.045
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 022275BA-F672-49C5-887B-CCF24A20848F | — | — | 0.902 |
| 2 | 0F797735-CCCA-4BEA-BB94-C524E7D0A875 | — | — | 0.889 |
| 3 | 6F4F72B3-E2B1-48DD-B9F4-C03AFCE79566 | — | — | 0.888 |
| 4 | 93708EED-CBE1-4B2E-A571-34316ACFE748 | — | — | 0.877 |
| 5 | A7D9F5B1-D8C2-440F-A0B7-8B5641C2DA66 | — | — | 0.876 |
| 6 | 656B6084-9C58-469A-BEAF-FFC1D089E658 | — | — | 0.871 |
| 7 | 0636DD62-C493-47CC-A120-9759FB6980CD | — | — | 0.870 |
| 8 | 46C5EF69-5EAF-4FBA-BE47-28A8E7F3D9A2 | — | — | 0.863 |
| 9 | 85EE23A9-B5E4-49F7-A504-CEF2EB4E4E7E | — | — | 0.858 |
| 10 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.406 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.403 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.351 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.329 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.323 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.319 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.298 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.287 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.269 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.258 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.257 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.254 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.251 | Inavolisib | — uncovered |
| APOPTOSIS | 0.239 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.192 | Inavolisib | — uncovered |